Hyperbaric oxygen in the treatment of invase fungal infections: A single-center experience

Israel Medical Association Journal

Volumn 9, Issue 5, 2007, Pages 355-357

  Segal, Eran ^a,b   Menhusen, Monty J ^b   Simmons, Shawn ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Aspergillus spp.; Hyperbaric oxygen; Invasive fungal infection; Mucormycosis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; ITRACONAZOLE; OXYGEN; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CHILD; CLINICAL ARTICLE; FEMALE; HUMAN; HYPERBARIC OXYGEN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MUCORALES; MUCORMYCOSIS; MYCOSIS; RETROSPECTIVE STUDY; SURVIVAL; SYMPTOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CHILD; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERBARIC OXYGENATION; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; MUCORMYCOSIS; RETROSPECTIVE STUDIES;

EID: 34249664964     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Sugar AM, Agents of mucormycosis and related species. In: Mandell GL, ed. Principles and Practice of Infectious Diseases: Philadelphia: Churchill Livingstone, 2000:2685-91.
2. Bigby TD, Serota ML, Tierney LM, Jr., Matthay MA. Clinical spectrum of pulmonary mucormycosis. Chest 1986;89:435-9.
3. Vandewoude KH, Blot SI, Benoit D, Colardyn F, Vogelaers D. Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence. J Hosp Infect 2004;56269-76.
4. Yeung CK, Cheng VC, Lie AK, Yuen KY. Invasive disease due to Mucorales: a case report and review of the literature. Hong Kong Med J 2001;17:180-8.
5. Chopra H, Dua K, Malhotra V, Gupta RP, Puri H. Invasive fungal sinusitis of isolated sphenoid sinus in immunocompetent subjects. Mycoses 2006;49:30-6.
6. Garcia -Covarrubias L, Barratt DM, Bartlett R, Metzinger S, Van Meter K. Invasive aspergillosis treated with adjunctive hyperbaric oxygenation: a retrospective clinical series at a single institution. South Med J 2002;95:450-6.
7. Couch L, Theilen F, Mader JT. Rhinocerebral mucormycosis with cerebral extension successfully treated with adjunctive hyperbaric oxygen therapy. Arch Otolaryngol Head Neck Surg 1988;114:791-4.
8. Price JC, Stevens DL. Hyperbaric oxygen in the treatment of rhinocerebral mucormycosis. Laryngoscope 1980;90(5 Pt 1):737-47.
9. Bentur Y, Shupak A, Ramon Y, et al. Hyperbaric oxygen therapy for cutaneous/soft-tissue zygomycosis complicating diabetes mellitus. Plast Reconstr Surg 1998;102:822-4.
10. Guevara N, Roy D, Dutruc-Rosset C, Santini J, Hofman P, Castillo L. Mucormycosis - early diagnosis and treatment. Rev Laryngol Otol Rhinol (Bord) 2004;125:127-31.
11. Yohai RA, Bullock JD, Aziz AA, Markert RJ, Survival factors in rhino-orbita-cerebral mucormycosis. Surv Ophthalmol 1994;39:3-22.
12. Talmi YP, Goldschmied-Reouven A, Bakon M, et al. Rhino-orbital and rhino-orbito-cerebral mucormycosis. Otolaryngol Head Neck Surg 2002; 127:22-31.
13. Mendoza-Ayala R, Tapia R, Salathe M. Spontaneously resolving pulmonary mucormycosis. Clin Infect Dis 1999;29:1335-6.
14. Gudewicz TM, Mader JT, Davis CP. Combined effects of hyperbaric oxygen and antifungal agents on the growth of Candida albicans. Aviat Space Environ Med 1987;58:673-8.
15. Bornside GH. Quantitative cidal activity of hyperbaric oxygen for opportunistic yeast pathogens. Aviat Space Environ Med 1978;49:1212-14.
16. Brown GL, Thomson PD, Mader JT, Hilton JG, Browne ME, Wells CH. Effects of hyperbaric oxygen upon S. aureus, Ps. aeruginosa and C. albicans. Aviat Space Environ Med 1979;50:717-20.
17. Barratt DM, Van Meter K, Asmar P, et al. Hyperbaric oxygen as an adjunct in zygomycosis: randomized controlled trial in a murine model. Antimicrob Agents Chemother 2001;45:3601-2.